The kinetics of peptide presentation by major histocompatibility complex class I (MHC-I) molecules may contribute to the efficacy of CD8 ؉ T cells. Whether all CD8 ؉ T-cell epitopes from a protein are presented by the same MHC-I molecule with similar kinetics is unknown. Here we show that CD8 ؉ T-cell epitopes derived from SIVmac239 Gag are presented with markedly different kinetics. We demonstrate that this discrepancy in presentation is not related to immunodominance but instead is due to differential requirements for epitope generation. These results illustrate that significant differences in presentation kinetics can exist among CD8 ؉ T-cell epitopes derived from the same viral protein.
Multiple factors contribute to the antiviral efficacy of CD8 ϩ T cells, including functional avidity (3), killing efficiency (14) , polyfunctionality (4) , evolutionary constraints on the epitope sequences (8, 12, 17) , and the kinetics of antigen presentation (1, 15) . Antigen presentation kinetics may be important because the earlier that an epitope is present on the surface of an infected cell, the greater the window of opportunity for CD8 ϩ T cells to recognize and eliminate the infected cell before release of progeny virus. The kinetics of CD8 ϩ T-cell epitope presentation, however, remain poorly defined.
We recently demonstrated that penetration of virion-associated proteins into the cytoplasm was sufficient to generate CD8 ϩ T-cell epitopes early after infection of a target cell (15) . However, a previous study showed that presentation of an immunodominant CD8 ϩ T-cell epitope derived from another viral structural protein, lymphocytic choriomeningitis virus nucleoprotein, depended upon de novo protein synthesis (10) . To determine if all CD8 ϩ T-cell epitopes derived from a viral protein are presented with similar kinetics, we investigated the ontogeny of several CD8 ϩ T-cell epitopes derived from the simian immunodeficiency virus (SIV) structural protein SIVmac239 Gag.
Gag-specific CD8 ؉ T cells recognize an epitope only after de novo protein synthesis. We previously demonstrated that early presentation of incoming, virion-derived Gag epitopes was maximal at 6 h postinfection, while presentation of epitopes due to de novo synthesis of Gag occurred between 18 and 24 h postinfection (15) . To determine whether all Gag CD8 ϩ T-cell epitopes could be presented early after infection, we performed the kinetic intracellular cytokine staining (KICS) assay as described previously (15, 16) using major histocompatibility complex class I (MHC-I)-matched CD4 ϩ T-cell targets and CD8 ϩ T cells specific for four different epitopes in Gag (Table  1) . We examined two time points to determine if the Gag epitopes present on the surface of infected cells were derived from incoming (6-h-postinfection) or newly synthesized (24-hpostinfection) Gag proteins.
As previously observed, the immunodominant Mamu-A*02-restricted Gag 71-79 GY9 and Mamu-A*01-restricted Gag 181-189 CM9 CD8
ϩ T-cell epitopes were efficiently presented by SIVinfected cells at both 6 and 24 h postinfection, indicating that these epitopes could be derived from both incoming and newly synthesized Gag proteins ( Fig. 1A and B) . Next, we investigated the kinetics of the Mamu-A*01-restricted subdominant Gag epitope Gag 254-262 QI9, which is derived from the same mature protein as Gag 181-189 CM9, Gag p27 CA . Surprisingly, the Gag 254-262 QI9 epitope was absent from the surface of infected cells early after infection, even though the epitope was efficiently presented to CD8 ϩ T cells late in the viral replication cycle (Fig. 1C) . We confirmed late-only presentation of Gag 254-262 QI9 by using 23 different CD8 ϩ T-cell clones and polyclonal cell lines (Table 1) .
Although both Mamu-A*01-restricted Gag epitopes are derived from the N-terminal domain of Gag p27 CA , they map to separate areas in the secondary structure of the mature protein. Gag 181-189 CM9 is located predominantly within ␣-helix 3 while Gag 254-262 QI9 is situated partially inside ␣-helix 7 in mature Gag p27 CA (Fig. 1E ). To determine if the location of Gag 254-262 QI9 in Gag p27 CA was responsible for the inability of infected cells to present the epitope early after infection, we mapped a new epitope contained at the end of ␣-helix 7 in Gag p27
CA , Mamu-B*48-restricted Gag 276-283 RI8 (Table  1 ; Fig. 1E ). Infected cells efficiently presented Gag 276-283 RI8 at both time points after infection, indicating that this new Gag epitope was generated from both virion-associated and newly synthesized Gag (Fig. 1D) . Therefore, it appeared that the location of Gag 254-262 QI9 near ␣-helix 7 of Gag p27
CA was likely not responsible for late presentation of this epitope.
Immunodominance is not responsible for the inability of Gag 254-262 QI9 to be recognized early. Gag 181-189 CM9 is the immunodominant epitope presented by Mamu-A*01 and binds to the MHC-I molecule with a higher affinity than does Gag 254-262 QI9 ( Fig. 2A) . A recent study demonstrated that immunodominant epitopes are more efficiently liberated from polypeptide precursors than subdominant epitopes (11) . Therefore, we hypothesized that the earlier presentation of Gag 181-189 CM9 was due to more efficient production of this epitope. This would enable Gag 181-189 CM9 to outcompete Gag 254-262 QI9 for access to MHC-I molecules in the endoplasmic reticulum. To test this hypothesis, we constructed a molecularly cloned mutant virus, SIVmac239-CM9(T2A), which contains a threonine-to-alanine alteration at the secondary anchor position of the Gag 181-189 CM9 epitope together with two compensatory substitutions outside the epitope that restore fitness of the epitope mutant virus. This escape mutation has previously been shown to reduce binding to the MHC-I molecule by Ͼ90% while minimally affecting the infectivity or replication kinetics of the virus (9) (Fig. 2A) . By drastically reducing the binding of Gag 181-189 CM9 to the MHC-I molecule, we hypothesized that Gag 254-262 QI9 would then be more likely to bind MHC-I and be presented early after infection.
The Mamu-A*02-restricted Gag 71-79 GY9 epitope lies in Gag p17
MA and was unaffected by the CM9(T2A) mutation. Therefore, it was still efficiently presented both early and late by cells infected with the mutant virus (Fig. 2B) . The Gag 181-189 CM9-specific CD8 ϩ T cells failed to recognize CD4 ϩ T cells infected with SIVmac239-CM9(T2A) at any time point during the assay, indicating that the escape mutation completely ablated presentation of the epitope (Fig. 2C) . Although Gag 181-189 CM9 presentation was abolished, Gag 254-262 QI9 was still not presented early (Fig. 2D ). These data indicate that the immunodominance of Gag 181-189 CM9 over Gag 254-262 QI9 does not play a role in the late-only presentation of the Gag 254-262 QI9 epitope. 
Gag 254-262 QI9 presentation requires de novo Gag protein synthesis. Gag 181-189 CM9-specific CD8
ϩ T cells exhibit a higher functional avidity (ϳ13.3 nM) than do those specific for Gag 254-262 QI9 (ϳ574 nM) (13) . Similar values were obtained for the CD8 ϩ T-cell clones used in the present study (data not shown). This difference might account for the inability of Gag 254-262 QI9-specific CD8 ϩ T cells to recognize infected cells early after infection, especially if the epitope were poorly processed from incoming Gag proteins. To explore this hypothesis, we infected CD4 ϩ T cells with increasing amounts of virus and examined the early time point for Gag 254-262 QI9 presentation. While increasing the input virus to as high as a multiplicity of infection of 10 boosted early presentation of Gag 181-189 CM9, we detected no presentation of Gag 254-262 QI9 at 6 h postinfection (data not shown). These data suggest that differences in functional avidity and epitope processing rates are likely not responsible for the lack of early Gag 254-262 QI9 presentation.
A previous study demonstrated that macrophages, but not CD4 ϩ T cells, were able to present CD8 ϩ T-cell epitopes derived from Gag proteins in the incoming virus particle (5). It remained possible, therefore, that CD4 ϩ T cells lack the antigen processing machinery required to derive the Gag 254-262 QI9 epitope from virion-associated Gag. We generated macrophages from CD14 ϩ monocytes cultured in the presence of 5 ng/ml macrophage colony-stimulating factor for 5 days. We synchronously infected these macrophages with the macrophage-tropic virus SIVmac316E and examined presentation of the Mamu-A*01-restricted Gag epitopes. Similarly to CD4 ϩ T cells, infected macrophages presented Gag 254-262 QI9 only late in the viral replication cycle, even though they presented Gag 181-189 CM9 both early and late (Fig. 3A and B) .
Finally, we examined the ability of CD4 ϩ T cells to present Gag-derived epitopes under conditions in which synthesis of viral proteins is blocked. CD4
ϩ T cells pulsed with the chemically inactivated virus AT-2 SIVmac239 still efficiently presented the Gag 71-79 GY9, Gag 181-189 CM9, and Gag 276-283 RI8 epitopes early after infection (Fig. 3C to E) . Residual presen- tation of these epitopes still occurred at 24 h postinfection, but the robust second wave of antigen presentation due to de novo protein synthesis of Gag observed previously was abolished (compare Fig. 1 with Fig. 3) . Interestingly, blocking viral protein synthesis completely eliminated presentation of Gag 254-262 QI9 (Fig. 3F) . Similar results were obtained using CD4 ϩ T cells infected with SIVmac239 in the presence of tenofovir (data not shown). These experiments indicate that de novo Gag protein synthesis is required for generation of Gag 254-262 QI9.
One possible explanation for Gag 254-262 QI9's dependence upon de novo protein synthesis is provided by the defective ribosomal product (DRiP) hypothesis, which posits that epitope generation is tightly linked to protein translation (20) . Since Gag 254-262 QI9 epitope generation is tied to synthesis of Gag, this epitope may be derived from a DRiP. In support of this explanation, a previous study demonstrated that human immunodeficiency virus (HIV) Gag is a rich source of DRiPs in infected cells (18) . However, we cannot exclude the possibility that generation of the Gag 254-262 QI9 epitope from mature, virion-associated Gag p27
CA is blocked due to posttranslational protein modifications. The precursor Gag p55 polyprotein is proteolytically cleaved to liberate mature Gag proteins such as Gag p27
CA , which undergoes dramatic conformational changes during maturation of the virus particle. These conformational rearrangements of Gag p27
CA during maturation of the virion may preclude proteasomal degradation of the region in virion-associated Gag p27
CA containing Gag 254-262 QI9. Furthermore, because maturation of the Gag proteins does not occur until after the virion buds from the cell (7), the inability of the antigen processing machinery to liberate the Gag 254-262 QI9 epitope from mature Gag would not become apparent until the virus particle infected a new cell.
HLA-B*57 and HLA-B*27 are associated with slow disease progression in HIV type 1 infections and are overrepresented in cohorts of elite controllers (6) . These MHC-I molecules also restrict immunodominant CD8 ϩ T-cell epitopes in Gag p27 CA , Gag 240-249 TW10 and Gag 262-271 KK10, respectively. These two responses may be important for establishing low viremia in elite controllers, as recent studies have indicated that these epitopes dominate the acute-phase CD8 ϩ T-cell response in HIV type 1 infection (2, 19) . Interestingly, these epitopes map to the same area of the Gag capsid protein as does Gag 254-262 QI9, the epitope that required de novo Gag synthesis for presentation. It would be of interest, therefore, to investigate the requirements for epitope generation of these two HLA-B*57-and HLA-B*27-restricted CD8 ϩ T-cell epitopes. While the direct relationship between epitope presentation kinetics and antiviral efficacy in CD8 ϩ T cells remains poorly defined, the kinetics of epitope expression on the surface of virally infected cells contribute to the antiviral capacity of CD8 ϩ T cells. The results presented here, therefore, imply that not all CD8 ϩ T cells directed at the same protein will be equally effective due to differences in epitope ontogeny. Additionally, these results suggest that caution must be applied when extending the characteristics of individual epitope-specific CD8 ϩ T-cell responses to all of the CD8 ϩ T-cell responses directed against the same viral protein.
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